Not Yet RecruitingNot Applicable

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

China200 participantsStarted 2026-04

Plain-language summary

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written and voluntarily given Informed Consent.
✓. Male or female ≥18 years of age at time of consent.
✓. Have the capacity to understand the study and be willing and able to comply with all protocol requirements.
✓. Participants with histologically confirmed or suspected tumors of the following types, but not limited to:

Exclusion criteria

✕. Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator.
✕. Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.
✕. Be a female who is pregnant or breastfeeding.

What they're measuring

The Diagnostic Sensitivity and Specificity of 18F-T2 PET/CT in the Evaluation of CAIX Positive Solid Tumors

Timeframe: From study completion to 1 month after completion

Incidence of Adverse Events [Safety and Tolerability]

Timeframe: 24 hours after the injection of 18F-T2

Trial details

NCT IDNCT07557225

SponsorPeking University First Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-09

Contact for this trial

Keting Tong

+86 010-83575252 1910301229@pku.edu.cn

View on ClinicalTrials.gov More Clear Cell Renal Cell Cancer (ccRCC) trials